SEC Form 4 · accession 0001209191-19-005738
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin John Meyer
Officer — Chief Medical Officer
Period of report
Jan 28, 2019
Accepted (ET)
Jan 29, 2019 · 3:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $8.11 | Jan 28, 2019 | M | 622 | D | — | Feb 3, 2019 | Class B common stock | 622 | 0 | D |
| Class B common stockF2 | — | Jan 28, 2019 | M | 622 | A | — | — | Class A common stock | 622 | 129,607 | D |
Explanation of responses
- F1The options vested in sixteen equal installments beginning on May 3, 2009.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.